"Takhzyro safely reduces monthly attack rate in adolescents with hereditary angioedema"
Takhzyro, a monoclonal antibody, was found to safely reduce monthly attack rates in adolescents with hereditary angioedema, according to research presented at the American Academy of Allergy, Asthma and Immunology annual meeting. Paula J. Busse, MD, FAAAAI, associate professor of medicine and clinical immunology at the Icahn School of Medicine at Mount Sinai, and colleagues conducted a phase 3 trial and then an open-label extension study of the efficacy and safety of lanadelumab in adolescents with HAE with C1-inhibitor deficiency. The researchers recorded the monthly attack rate (MAR) and other treatment-emergent adverse events (TEAEs).
— Paula J. Busse, MD, Associate Professor, Medicine, Clinical Immunology, Icahn School of Medicine at Mount Sinai